Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immune Checkpoint Therapy
Treatment Pembrolizumab
Drugstatus Approved
Drugbank ID DB09037
Checkpoints PD-1
Signature Type Protein
Signature PD-L1
Official Symbol CD274
Mode of action PROT_R_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trial phase 3
Description With approximately 8 additional months of follow-up,the data showed continued OS benefit with pembrolizumab over chemotherapy in the first-line treatment of patients with advanced NSCLC whose tumors expressed high levels of PD-L1; the18-month OS rate of 61.2% in the pembrolizumab groupcompared with 43% in the chemotherapy group, and the 12-monthOS rate of 70.3% in the pembrolizumab group compared with54.8% in the chemotherapy group.
PMID 29153898
Title The Significance of the PD-L4 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers